Saturday 17 October 2026
Export CLSDQ’s income statement to Excel — free account
Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
0.25
0.00
0.00%
Follow CLSDQ
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
42.16 | 18.77 | 14.96 | 6.24 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.35) | (12.12) | (13.18) | (3.79) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
30.95 | 15.51 | 13.04 | 4.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.09) | (2.58) | (2.50) | (0.72) | |
EV/FCF |
(2.01) | (2.47) | (2.44) | (0.71) | |
Quick Ratio |
4.28 | 3.03 | 3.34 | 2.55 | |
Current Ratio |
4.44 | 3.19 | 3.87 | 2.98 | |
Net Debt/EBITDA |
2.81 | 2.66 | 2.69 | 0.98 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.13 | 0.17 | 0.16 | |
Operating CF/Net income |
0.72 | 0.71 | 1.05 | 0.92 | |
Capex/Depreciation |
(17.08) | (0.11) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,386.93% | 191.55% | 321.95% | 1,459.20% | |
Selling, General and Administrative Expense of Revenue |
1,000.65% | 121.20% | 503.25% | 2,143.28% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
381.05% | 30.94% | 141.06% | 371.14% | |
Graham Net Nets |
(0.61) | (0.70) | (0.84) | (2.76) | |
Graham Number |
35.38 | 35.18 | 34.23 | 34.69 | |
Earnings Yield |
(49.45%) | (44.64%) | (46.23%) | (130.68%) | |
Free Cash Flow Yield |
(36.60%) | (33.41%) | (35.68%) | (104.65%) | |
Revenue per Share |
0.06 | 0.45 | 0.09 | 0.04 | |
Operating CF per Share |
(1.07) | (1.14) | (0.91) | (1.05) | |
Capex per Share |
(0.09) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.16) | (1.14) | (0.91) | (1.05) | |
Cash per Share |
4.07 | 2.66 | 1.81 | 1.30 | |
Shareholders Equity per Share |
(7.89) | (8.95) | (9.39) | (10.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(7.89) | (8.95) | (9.39) | (10.31) | |
Free Cash Flow |
(5.70) | (5.84) | (4.73) | (5.48) | |
Working Capital |
16.48 | 10.95 | 8.74 | 5.48 | |
Capital Expenditures |
(0.44) | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
(42.71) | (49.61) | (52.28) | (57.34) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.45 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.38 | 1.21 | 0.64 | 0.53 | |
Average Payables |
1.83 | 1.64 | 1.35 | 1.58 | |
Average Assets |
29.57 | 29.91 | 24.63 | 20.40 | |
Average Common Equity |
(27.38) | (33.86) | (38.51) | (44.37) |
Columns are period end dates